ID   COR-L32
AC   CVCL_2413
SY   Cor L32; CORL32
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03473036
DR   cancercelllines; CVCL_2413
DR   Cell_Model_Passport; SIDM00508
DR   Cosmic-CLP; 1322212
DR   DepMap; ACH-001489
DR   ECACC; 96020744
DR   EGA; EGAS00001000978
DR   GDSC; 1322212
DR   GEO; GSM1669701
DR   PharmacoDB; CORL32_247_2019
DR   PRIDE; PXD030304
DR   Wikidata; Q54814286
RX   PubMed=2998422;
RX   PubMed=25877200;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=1.46%; East Asian, South=0%; South Asian=0%; European, North=70.96%; European, South=27.58% (PubMed=30894373).
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): Cosmic-CLP; DepMap; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 8 (PubMed=25877200)
ST   D13S317: 8,11 (Cosmic-CLP; DepMap)
ST   D16S539: 9,11
ST   D18S51: 13
ST   D21S11: 27,32.2
ST   D3S1358: 14,17
ST   D5S818: 12
ST   D7S820: 8,10
ST   D8S1179: 14,15
ST   FGA: 21
ST   Penta D: 12,13
ST   Penta E: 7,10
ST   TH01: 7,9.3
ST   TPOX: 10
ST   vWA: 14
DI   NCIt; C3493; Lung squamous cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 28
//
RX   PubMed=2998422; DOI=10.1038/bjc.1985.220;
RA   Baillie-Johnson H., Twentyman P.R., Fox N.E., Walls G.A., Workman P.,
RA   Watson J.V., Johnson N., Reeve J.G., Bleehen N.M.;
RT   "Establishment and characterisation of cell lines from patients with
RT   lung cancer (predominantly small cell carcinoma).";
RL   Br. J. Cancer 52:495-504(1985).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//